Peripheral Artery Disease Management

Introduction

Peripheral artery disease (PAD) typically presents with intermittent claudication, rest pain, and tissue damage that can progress to limb-threatening ischemia if left untreated, with femoral artery blockage, superficial femoral artery (SFA) occlusion, and popliteal and tibial occlusions having distinct clinical presentations 1, 2

Diagnosis

The diagnosis of PAD should be based on a comprehensive vascular assessment, with the initial non-invasive diagnostic test being the Ankle-Brachial Index (ABI) with ABI ≤0.90 confirming PAD diagnosis, and the Toe-Brachial Index (TBI) used when ABI is abnormally high (>1.4) due to vessel calcification, as recommended by the European Society of Cardiology 3
Duplex Ultrasound (DUS) is the first-line imaging method to confirm lesions and their location, while CT Angiography (CTA) or MR Angiography (MRA) are used for anatomical characterization of lesions and planning revascularization, and Digital Subtraction Angiography (DSA) is often required for guiding interventional procedures, as recommended by the European Society of Cardiology 1
Pulse Volume Recording (PVR) is a valuable screening tool for chronic limb ischemia, as recommended by the American College of Radiology 4

Medical Therapy

High-intensity statin therapy is recommended for all PAD patients, with a target LDL-C reduction ≥50% from baseline and goal <1.4 mmol/L (<55 mg/dL), according to the European Society of Cardiology 3
Statins, such as high-intensity statin therapy, improve cardiovascular outcomes and walking distance, and are recommended for all PAD patients regardless of cholesterol levels, as recommended by the American College of Cardiology and the European Society of Cardiology 1, 5
Antihypertensives, such as calcium antagonists or ACEIs/ARBs, are preferred for their peripheral arterial dilation properties, and are recommended to target appropriate blood pressure, as recommended by the American College of Cardiology and the European Society of Cardiology 1, 5
Antiplatelet therapy with aspirin (75-325 mg daily) or clopidogrel (75 mg daily) is recommended to reduce cardiovascular events in PAD patients, with clopidogrel preferred over aspirin alone, and a combination of low-dose rivaroxaban and aspirin may be considered for high ischemic risk patients, as recommended by the American Heart Association and the American College of Cardiology 5, 6, 7, 2
Glycemic control with a target HbA1c < 7% is recommended for patients with diabetes, as recommended by the American Diabetes Association and the American Heart Association 6
Cilostazol (100mg twice daily) is recommended for patients with claudication, with an improvement in walking distance of 40-60%, and pentoxifylline 400 mg three times daily is a second-line alternative when cilostazol is contraindicated, as reported by the American College of Cardiology 6, 5, 8

Lifestyle Modifications

Smoking cessation is crucial for symptom improvement and survival, and the American College of Cardiology recommends advising patients to quit smoking at every visit with pharmacotherapy support (varenicline, bupropion, nicotine replacement), as recommended by the American College of Cardiology 5, 9
A Mediterranean diet is recommended for patients with PAD, with a target BMI ≤25 kg/m², as suggested by the European Heart Journal 10
Regular exercise, such as a supervised exercise program (Class I, Level A recommendation) with 30-45 minutes per session, at least 3 sessions per week, and a minimum 12-week program, is recommended to improve functional status and reduce cardiovascular risk, as recommended by the American College of Cardiology 6, 5

Revascularization

Revascularization should be considered for patients with impaired quality of life after 3 months of optimal medical therapy and exercise, as recommended by the European Society of Cardiology 3
Revascularization should be performed as soon as possible in patients with chronic limb-threatening ischemia (CLTI), according to the European Society of Cardiology 3
For short lesions (<25 cm), an endovascular-first approach with drug-eluting treatment is recommended as the first-choice strategy for femoro-popliteal lesions, as suggested by the European Society of Cardiology 3
For long lesions (≥25 cm), bypass surgery should be considered when autologous vein is available and life expectancy >2 years, according to the European Society of Cardiology 3
Aorto-(bi)femoral bypass should be considered in surgical candidates with aorto-iliac occlusions, as recommended by the European Society of Cardiology and the American College of Cardiology 1, 6
Primary stenting with nitinol stents is the recommended first-line treatment for superficial femoral artery stenosis to prevent progression to occlusion, as it provides 20-30% lower restenosis rates compared to angioplasty alone, according to the European Heart Journal guidelines 10

Follow-up and Surveillance

Patients should undergo at least annual assessment of clinical and functional status, medication adherence, limb symptoms, and cardiovascular risk factors, as recommended by the European Society of Cardiology and the American College of Cardiology 3, 2, 1
Duplex ultrasound assessment should be performed as needed, according to the European Society of Cardiology 3
For infrainguinal autogenous vein bypass grafts, duplex ultrasound surveillance should be performed at 1-3 months, then at 6 and 12 months, and annually thereafter, as recommended by the American College of Cardiology 11
For endovascular procedures, ABI and arterial duplex ultrasound surveillance should be performed at 1-3 months, then at 6 and 12 months, and annually thereafter, according to the American College of Cardiology 11

Chronic Limb-Threatening Ischemia (CLTI) Management

Patients with CLTI should be managed by a vascular team, as recommended by the European Society of Cardiology 3
For patients with CLTI and ulcers, offloading mechanical tissue stress is indicated, according to the European Society of Cardiology 3
Lower-limb exercise training is not recommended in patients with CLTI and wounds, as suggested by the European Society of Cardiology 3

Pain Management

Multimodal analgesia, combining drugs with different mechanisms, can improve pain relief, as suggested by the European Society of Anaesthesiology 12
Opioid titration, such as intravenous morphine titration, can be used for severe pain, while adjuncts like paracetamol and low-dose ketamine can reduce opioid requirements, according to the European Society of Anaesthesiology 12
Regional anesthesia, such as femoral nerve blocks, can provide effective pain relief and reduce opioid needs, as recommended by the European Society of Anaesthesiology 12

Contraindications and Pitfalls

Anticoagulation should NOT be used to reduce cardiovascular events in PAD patients (Class III: Harm), as recommended by the American College of Cardiology 5
Chelation therapy (e.g., ethylenediaminetetraacetic acid) is not indicated and may have harmful effects, as recommended by the American College of Cardiology 6
Unstructured home-based walking programs should be avoided as they are not efficacious, as recommended by the American College of Cardiology 5
Common pitfalls in PAD management include inadequate antiplatelet therapy, premature revascularization, focusing only on limb symptoms while neglecting cardiovascular risk reduction, underutilization of exercise therapy, and inadequate medical therapy, as reported by the American College of Cardiology, the American Heart Association, and the European Society of Cardiology 6, 2, 4, 3, 5, 6, 10